Targeted therapies for metastatic esophagogastric cancer

Current Treatment Options in Oncology

Volumn 12, Issue 1, 2011, Pages 46-60

  Reddy, Deepa ^b   Wainberg, Zev A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; AVASTATIN; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; K RAS PROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; SORAFENIB; SUNITINIB; TELATINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WARFARIN;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COUGHING; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TARGETING; EDEMA; ELECTROLYTE DISTURBANCE; ESOPHAGUS CANCER; FATIGUE; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; LOW DRUG DOSE; MAGNESIUM DEFICIENCY; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SKIN MANIFESTATION; STOMACH CANCER; STOMATITIS; UNSPECIFIED SIDE EFFECT; WEAKNESS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ESOPHAGEAL NEOPLASMS; HUMANS; PROGNOSIS; STOMACH NEOPLASMS;

EID: 79957978274     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0138-4     Document Type: Article

References (74)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics. CA Cancer J Clin 2009, 59:225.
2. Bollschweiler E, Wolfgarten E, Gutschow C, Hölscher AH: Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001, 92:549.
3. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr.: Rising incidence of adenocarcinoma of the esophagus, gastric cardia. JAMA 1991, 265:1287.
4. Daly JM, Karnell LH, Menck HR: National Cancer Data Base report on esophageal carcinoma. Cancer 1996, 78:1820.
5. Brown LM, Devesa SS: Epidemiologic trends in esophageal, gastric cancer in the United States. Surg Oncol Clin N Am 2002, 11:235.
6. El-Serag HB, Mason AC, Petersen N, Key CR: Epidemiological differences between adenocarcinoma of the oesophagus, adenocarcinoma of the gastric cardia in the USA. Gut 2002, 50:368.
7. Ferlay J Bray F Parkin DM, Pisani P (Eds): Gobocan 2000: Cancer Incidence and Mortality Worldwide (IARC Cancer Bases No. 5). Lyon: IARC Press, 2001.
8. Lau M, Le A, El-Serag HB: Noncardia gastric adenocarcinoma remains an important, deadly cancer in the United States: secular trends in incidence, survival. Am J Gastroenterol 2006, 101:2485.
9. Orringer MB, Marshall B, Iannettoni MD: Transhiatel esophagectomy: clinical experience and refinements. Ann Surg 1999, 230:392-400.
10. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone in resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
11. Tepper J, Krasna MJ, Niedzwiecki D, et al.: Phase III trial of trimodality therapy with cisplatin, flourouracil, radiatiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092.
12. Walsh TN, Noonan N, Hollywood D, et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462-467. (Pubitemid 26269945)
13. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
14. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003, 349:2241-2252. (Pubitemid 37485141)
15. al-Kasspooles M, Moore JH, Orringer MB, Beer DG: Amplification and overexpression of the EGFR and erbB-2 genes in human esophageal adenocarcinoma. Int J Cancer 1993, 54:213-219. (Pubitemid 23154884)
16. Ross JS, McKenna BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001, 19:554-568. (Pubitemid 32619394)
17. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS: Her-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000, 31:35-39. (Pubitemid 30054384)
18. Sauter G, Lee J, Bartlett JM, et al.: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. Clin Oncol 2009, 27(8):1323-1333.
19. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51. (Pubitemid 47026733)
20. Cortés-Funes H, Rivera F, Alés I, et al.: Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007, 25(18): s4613.
21. Egamberdiev DM, Djuraev MD, Tuydjanova K, Nematov ON: Our experience in the use of Trastuzumab in patients with advanced stomach cancer. Ann Oncol 2010, 21(8):839.
22. Bang YJ, Van Cutsem E, Feyereislova A, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010, 376:687-697. First randomized trial to show the benefit of a targeted therapy in esophagogastric cancers. Established a new standard for HER2 positive EGC.
23. Satoh T, Leon J, Lopez RI, et al.: Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. In Proc GI Cancer Symposium; 2010.
24. Iqbal S, Goldman B, Lenz H, Fenoglio-Preiser C, Blanke C: S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients with advanced or metastatic gastric cancer. J Clin Oncol 2007, 25:4621.
25. Hecht J, Urba S, Koehler M, et al.: Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. In ASCO 2008, vol 43; 2008 (abstract).
26. Galsky M, Von Hoff D, Neubauer M, et al.: Targetspecific, histology-independent, randomized discontinuation study of lapatinib in patients with her-2 amplified solid tumors. J Clin Oncol 2009, 27:3541.
27. Itakura Y, Sasano H, Shiga C, et al.: Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994, 74:795-804. (Pubitemid 24237457)
28. Kitagawa Y, Ueda M, Ando N, et al.: Epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996, 2:909-914. (Pubitemid 26168944)
29. Gibault L, Metges JP, Conan-Charlet V, et al.: Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005, 93:107-115. (Pubitemid 41076258)
30. Wilkinson NW, Black JD, Roukhadze E, et al.: Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004, 8:448-453. (Pubitemid 38561209)
31. Han SW, Oh DY, Im SA, et al.: Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009, 100:298-304.
32. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al.: Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006, 24:1612-1619. (Pubitemid 46638785)
33. Imai K, Takaoka A: Comparing antibody and smallmolecule therapies for cancer. Nat Rev Cancer 2006, 6:714-727. (Pubitemid 44286003)
34. Pinto C, Di Fabio F, Siena S, et al.: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007, 18:510-517. (Pubitemid 46359631)
35. Moehler M, Mueller A, Trarbach T, et al.: Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2010; Nov. 30 (Epub ahead of print).
36. Lordick F, Luber B, Lorenzen S, et al.: Cetuximab plus oxaliplatin/leucovorin/5-flourouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010, 102:500-505.
37. Lorenzen S, Schuster T, Porschen R, et al.: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009, 20:1667-1673.
38. Yeh K, Hsu C, Hsu C, et al.: Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the firstline treatment of advanced gastric cancer. J Clin Oncol 2009, 27:4567 abstract.
39. Zhang X, Xu J, Shen L, et al.: A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer. In Proc GI ASCO 2009;2009: LBA39 (abstract).
40. Pinto C, Di Fabio F, Barone C, et al.: Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009, 101:1261-1268.
41. Woell E, Greil R, Eisterer W, et al.: Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the arbeitsgemeinschaft medikamentoese tumortherapie (AGMT). J Clin Oncol 2009, 27:4538 abstract.
42. Enzinger PC, Burtness B, Hollis D, et al.: CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010, 28:4006 abstract. First randomized study with an EGFR inhibitor to be reported in EGC. Will be the basis for future studies in this disease.
43. Gold PJ, Goldman B, Iqbal S, et al.: Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol 2010, 5:1472-1476.
44. Ku G, Shah M, Tang L, et al.: Cetuximab (C225) plus irinotecan/cisplatin (CPT/CDDP) for CPT/CDDP-refractory esophageal cancer. In Proc GI ASCO 2008, vol 54; 2008 (abstract).
45. Tebbutt N, Sourjina T, Strickland A, et al.: ATTAX2-docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG. In Proc GI ASCO 2008, vol 87; 2008 (abstract).
46. Schønnemann K, Bjerregaard J, Jensen H, et al.: Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer. In Proc GI ASCO 2009, vol 73; 2009 (abstract).
47. Figlin R, Belldegrun A, Crawford J, et al.: ABX-EGF, a fully human antiepidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002, 21:35 (abstract).
48. Okines AF, Ashley SE, Cunningham D, et al.: Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. Clin Oncol 2010, 28(25):3945-3950.
49. Vanhoefer U, Tewes M, Rojo F, et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004, 22:175-184. (Pubitemid 41095130)
50. Rao S, Starling N, Cunningham D, et al.: Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008, 99:868-874.
51. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al.: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006, 24:4922-4927. First study to look at the effect of a targeted therapy on separate anatomic areas: gastroesophagus junction and distal stomach. (Pubitemid 46630921)
52. Wainberg ZA, Lin L, Di Carlo B et al.: Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ). J Clin Oncol 2010, 28:15s (suppl; abstract 4050).
53. Ferry DR, Anderson M, Beddard K, et al.: A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007, 13:5869-5875. (Pubitemid 47583913)
54. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25. (Pubitemid 27076453)
55. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma Association with angiogenesis and tumor progression. Cancer 1997, 79:206-213. (Pubitemid 27029883)
56. Kitadai Y, Haruma K, Tokutomi T, et al.: Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998, 4:2195-2200. (Pubitemid 28415667)
57. Kleespies A, Guba M, Jauch KW, Bruns CJ: Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004, 87:95-104. (Pubitemid 39079657)
58. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M: Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000, 6:1161-1168. (Pubitemid 30159380)
59. Imdahl A, Bognar G, Schulte-Monting J, et al.: Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002, 21:657-663. (Pubitemid 34257953)
60. Shah MA, Ramanathan RK, Ilson DH, et al.: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24:5201-5206. (Pubitemid 46631363)
61. Kelsen D, Jhawer M, Ilson D, et al.: Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial. J Clin Oncol 2009, 27:4512 abstract.
62. Enzinger P, Ryan D, Regan E, et al.: Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol 2008, 26:4552 abstract.
63. El-Rayes B, Patel B, Zalupski M, et al.: A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer, American Society of Clinical Oncology, Orlando, FL. J Clin Oncol 2009, 27:4563.
64. Enzinger P, Fidias P, Meyerhardt J, et al.: Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. In Proc GI ASCO 2006, vol 68; 2006 (abstract).
65. Kang Y, Ohtsu A, Van Cutsem E, et al.: AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 2010, 28:4007 abstract. First randomized trial reported of an anti-VEGF therapy in EGC.
66. Bang YJ, Kang YK, Kang WK, et al.: Sunitinib as second-line treatment for advanced gastric cancer. In Invest New Drugs 2010; May 12 (Epub ahead of print).
67. Sun W, Powell M, O'Dwyer P, Catalano P, Ansari RH, Benson AB: Phase II study of sorafenib in combnation with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma; ECOG 5203. J Clin Oncol 2010, 28:2947-2951.
68. Ko AH, Tabernero J, Garcia De Paredes M, et al.: Phase II study of telatinib (T) in combination with capecitabine (X) and ciplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction (GEJ). J Clin Oncol 2010, 28:14575 abstract.
69. Yu G, Wang J, Chen Y, et al.: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 2009, 15:1821-1829.
70. Doi T, Muro K, Boku N, et al.: Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010, 28:1904-1910. First study reported of an mTOR inhibitor in EGC, is the basis for an ongoing randomized trial.
71. Jhawer M, Kindler H, Wainberg Z, et al.: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study. J Clin Oncol 2009, 27:4502 abstract.
72. Bramhall SR, Hallissey MT, Whiting J, et al.: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002, 86:1864-1870.
73. Ajani JA, Jiang Y, Faust J, et al.: A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 2006, 24:353-357.
74. Ku GY, Ilson DH, Schwartz LH, et al.: Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 2008, 62:875-880.